Clinical trials: Type I Diabetes
Type 1 Diabetes
CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Longitudinal Study
Glycaemic control is an important aspect of Type 1 diabetes (T1D) management for diabetologists and patients alike. Evidence suggests continuous subcutaneous insulin infusion (CSII) is an effective method of achieving this.
- Trial name
- NCT02258932
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Liverpool John Moores University
Insulin Dependent Diabetes Mellitus, Feeding and Eating Disorders
The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes
Type 1 diabetes is an autoimmune health condition that requires daily injections of insulin. Insulin allows the body to use energy from carbohydrates in food.
- Conditions
- Insulin Dependent Diabetes Mellitus, Feeding and Eating Disorders, Eating Behavior, Type 1 Diabetes
- Trial name
- NCT07348432
- Testing
- Automated Insulin Delivery (AID) Systems, Carbohydrate Counting Inaccuracy Percentage
- Where
- Canada
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- McGill University
Type 1 Diabetes Mellitus
Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
The overall purpose of this trial is to assess the efficacy and safety of using oral verapamil in subjects with recent onset T1D in order to downregulate TXNIP and enhance the patients' endogenous beta cell mass and insulin…
- Trial name
- NCT02372253
- Testing
- Verapamil
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin…
- Trial name
- NCT01984372
- Testing
- insulin degludec
- Where
- Japan
- Volunteers
- 6,163 people
- Sponsor
- Novo Nordisk A/S
Type One Diabetes Mellitus
Evaluation of a Mobile Application Designed to Support Type 1 Diabetic Patients in Adjusting Their Insulin Doses.
Title: Evaluating a Mobile Application for Insulin Management in Iraqi Type 1 Diabetes Patients. The goal of this clinical trial is to determine whether a mobile health application can improve insulin management and blood sugar…
- Trial name
- NCT07234500
- Testing
- mHealth Mobile Application, Standard Care (in control arm)
- Where
- Iraq
- Volunteers
- 50 people
- Sponsor
- University of Baghdad
Type 2 Diabetes
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01965509
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
End-Stage Renal Disease (ESRD) Chronic Kidney Disease, Stage 5 Renal Regeneration Anuria Diabetic Nephropathy, Anuria
Clinical Observation of Renal Function Reactivation Following a GRAS-Based Protocol in Patients With Chronic Kidney Disease and Long-Term Renal Arrest.
This observational study documents the impact of a specific oral protocol (based on FDA-GRAS ingredients) on patients with Stage 5 Chronic Kidney Disease (CKD).
- Conditions
- End-Stage Renal Disease (ESRD) Chronic Kidney Disease, Stage 5 Renal Regeneration Anuria Diabetic Nephropathy, Anuria, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Stage 5
- Trial name
- NCT07555327
- Testing
- CSR-CKD Oral Protocol
- Where
- Algeria
- Volunteers
- 8 people
- Sponsor
- Amar h Zireg
Diabetes Mellitus Type 1, Glucose Metabolism Disorder
Real-life Follow-up of the Physical Activity in Type 1 Diabetes Participants Equipped With an Insulin Pump With Hybrid Closed Loop
This is a non-interventional, prospective, multi-site study conducted in France among adults with type 1 diabetes mellitus using automated insulin delivery (AID) systems and engaging in at least two exercise sessions per week…
- Conditions
- Diabetes Mellitus Type 1, Glucose Metabolism Disorder, Glycemic Control for Diabetes Mellitus, Fear of Hypoglycemia
- Trial name
- RAPPID (NCT07015970)
- Testing
- No Intervention: Observational Cohort
- Where
- 4 sites in France
- Volunteers
- 87 people
- Sponsor
- ISIS Diabete Service
Type 1 Diabetes Mellitis, Celiac Disease
Metabolic Control and Glycemic Variability in Type 1 Diabetes and Celiac Disease
This is an observational, retrospective study focused on differences of time-in-range and glycemic variability between a cohort of patients with both type 1 diabetes and celiac disease, and a cohort of patients with only type 1…
- Trial name
- NCT06717841
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diabetes, Diabetes Mellitus, Type 1
Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus
This study is conducted in Europe. The aim of this non-interventional study is to investigate the safety and effectiveness of insulin degludec (Tresiba®) in a real world population with type 1 (T1DM) and 2 (T2DM) diabetes…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- ReFLeCT (NCT02392117)
- Testing
- insulin degludec
- Where
- 8 sites in Denmark, Germany and 6 more
- Volunteers
- 1,262 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Type 2 Diabetes (T2DM)
CGM Use in Non-insulin Patients With DM2
The U.S. Food and Drug Administration (FDA) has approved multiple Continuous Glucose Monitoring (CGM) devices from different manufacturers to be used as an aide in patients with type 1 and type 2 diabetes who require medications…
- Conditions
- Diabetes, Type 2 Diabetes (T2DM), Obesity Type 2 Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
- Trial name
- CGM-DWI (NCT07128342)
- Testing
- CGM Group, FSBG group
- Volunteers
- 100 people
- Sponsor
- Milwaukee VA Medical Center
Diabetes Mellitus Type I, Hypoglycemia
Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose
Diabetes mellitus type I (DMI) is characterized by lack of endogenous insulin and these patients are 100% dependent on insulin substitution to survive.
- Trial name
- NCT01919788
- Testing
- Insulin (Insuman Rapid), Glucose, Saline
- Where
- Denmark
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Type 1 Diabetes
Screening For Social Determinants Of Health In Routine Diabetes Care
Social determinants of health (SDOH) exert a powerful influence on the everyday management of type 1 diabetes (T1D) and short and long term outcomes of T1D.
- Trial name
- SDOH (NCT07706803)
- Testing
- Social Determinants of Health (SDOH) Screening and Referral
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, Los Angeles
Type 1 Diabetes Mellitus
User Performance and System Accuracy Evaluations Using Glucose Adjustment
This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment.
- Trial name
- NCT02374879
- Testing
- Blood Glucose Monitoring Systems.
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- LifeScan
Type1diabetes
HIT on Hypoglycaemic Risk in T1D
There is clear evidence that regular exercise improves wellbeing and reduces the risk of diabetes related complications in people with type 1 diabetes. However, many people with type 1 diabetes do not exercise regularly.
- Trial name
- NCT05044442
- Testing
- moderate intensity continous training, high intensity interval training
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Liverpool John Moores University
Diabetes Mellitus, Type 1
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus.
- Trial name
- NCT00137046
- Testing
- Subcutaneous Insulin, Inhaled Insulin
- Where
- 73 sites in United States, Argentina and 3 more
- Volunteers
- 582 people
- Sponsor
- Pfizer
Type 1 Diabetes (T1D), Islets of Langerhans Transplantation
Efficacy of Islet Re-transplantation After Failure of Beta-cell Replacement
Islet transplantation and pancreas transplantation are established therapeutic options for selected individuals with type 1 diabetes experiencing severe glycemic instability and recurrent hypoglycemia.
- Trial name
- MULT-ILOT (NCT07666789)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Montpellier
Type 1 Diabetes
Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in South Africa
Diabetes mellitus (diabetes) is a chronic condition that represents a major public health and clinical concern. Self-monitoring of blood glucose (SMBG) is a critical part of the care of individuals with diabetes.
- Trial name
- ACCEDE (NCT05944718)
- Testing
- Continuous glucose monitor
- Where
- 3 sites in South Africa
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Type 1 Diabetes
Intranasal Insulin for Prevention of Type 1 Diabetes
Children born in Turku, Oulu and Tampere university cities in Finland are screened at birth for HLA alleles that carry increased risk to or protection from development of type 1 diabetes.
- Trial name
- NCT00223613
- Testing
- daily intranasal administration of insulin
- Where
- Finland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Turku
Type 1 Diabetes
Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions
The main objective of this study is to determine whether home use of day and night closed loop insulin delivery under free living conditions applying faster insulin aspart (FiAsp) is non-inferior to home use of closed-loop…
- Trial name
- AP@Home04_P3 (NCT04055480)
- Testing
- Closed-loop using standard rapid-acting insulin, Closed-loop using faster insulin aspart
- Where
- 4 sites in Austria, Switzerland and 1 more
- Volunteers
- 25 people
- Sponsor
- University of Cambridge